Literature DB >> 8545886

Expression of cytokines and immune mediators during chronic liver allograft rejection.

M Hayashi1, O M Martinez, R Garcia-Kennedy, S So, C O Esquivel, S M Krams.   

Abstract

To determine the immune processes involved in chronic liver allograft rejection (CR) we examined in situ cytokine production in tissue from 15 patients with both clinical and histopathological diagnoses of CR. Total RNA was isolated from liver samples, reverse-transcribed and analyzed by RT-PCR for the production of proinflammatory cytokines and immunoregulatory mediators. Transcripts for the Th1-like cytokines IL-2 and IFN-gamma were detected in 53.3% and 46.7% of CR grafts, while they were detected in only 16% and 0% of stable grafts, respectively. The cytotoxic T cell mediator granzyme B was expressed in the majority of liver grafts undergoing CR, but was expressed only in a minority of stable grafts (80% vs. 16%, P < 0.05). The T cell product IL-5 was also significantly upregulated in CR as compared with stable livers (80% vs. 16%, P < 0.01). Other Th2 cytokines--IL-4 and IL-10--and macrophage products--IL-1 beta, IL-6, IL-8, TGF-beta, and TNF-alpha--were not substantially upregulated in CR grafts as compared with stable grafts. PDGF-beta transcripts were detected in the majority of the CR grafts, but were not detected in stable liver grafts (73% vs. 0, P < 0.05). By immunohistochemical staining, we observed that CD3+CD4+, and CD3+CD4- T cells were detected in CR grafts along with CD20+ B cells and CD68+ macrophages. There was, however, a predominant infiltration of CD3+CD4+ lymphocytes. Taken together, these data suggest that infiltrating cells produce proinflammatory and immunoregulatory cytokines that have a role in mediating graft damage in CR.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8545886     DOI: 10.1097/00007890-199560120-00027

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  9 in total

1.  Inhibition of interleukin-12 production by auranofin, an anti-rheumatic gold compound, deviates CD4(+) T cells from the Th1 to the Th2 pathway.

Authors:  T S Kim; B Y Kang; M H Lee; Y K Choe; S Y Hwang
Journal:  Br J Pharmacol       Date:  2001-10       Impact factor: 8.739

2.  Retinoid-mediated inhibition of interleukin-12 production in mouse macrophages suppresses Th1 cytokine profile in CD4(+) T cells.

Authors:  B Y Kang; S W Chung; S H Kim; S N Kang; Y K Choe; T S Kim
Journal:  Br J Pharmacol       Date:  2000-06       Impact factor: 8.739

Review 3.  Chronic rejection. A general overview of histopathology and pathophysiology with emphasis on liver, heart and intestinal allografts.

Authors:  A J Demetris; N Murase; R G Lee; P Randhawa; A Zeevi; S Pham; R Duquesnoy; J J Fung; T E Starzl
Journal:  Ann Transplant       Date:  1997       Impact factor: 1.530

4.  All-trans-retinoic acid suppresses interferon-gamma and tumor necrosis factor-alpha; a possible therapeutic agent for rheumatoid arthritis.

Authors:  Yuji Nozaki; Chise Tamaki; Toshiaki Yamagata; Masafumi Sugiyama; Shinya Ikoma; Koji Kinoshita; Masanori Funauchi
Journal:  Rheumatol Int       Date:  2005-11-15       Impact factor: 2.631

5.  Pathology of Chronic Rejection: An Overview of Common Findings and Observations About Pathogenic Mechanisms and Possible Prevention.

Authors:  A J Demetris; N Murase; T E Starzl; J J Fung
Journal:  Graft (Georget Tex)       Date:  1998-05

6.  Efficient induction of an antigen-specific, T helper type 1 immune response by interleukin-12-secreting fibroblasts.

Authors:  T S Kim; K M Kim; B A Shin; S Y Hwang
Journal:  Immunology       Date:  2000-06       Impact factor: 7.397

7.  Curcumin inhibits Th1 cytokine profile in CD4+ T cells by suppressing interleukin-12 production in macrophages.

Authors:  B Y Kang; Y J Song; K M Kim; Y K Choe; S Y Hwang; T S Kim
Journal:  Br J Pharmacol       Date:  1999-09       Impact factor: 8.739

8.  Recurrent hepatitis C in liver allografts: prospective assessment of diagnostic accuracy, identification of pitfalls, and observations about pathogenesis.

Authors:  A J Demetris; B Eghtesad; A Marcos; K Ruppert; M A Nalesnik; P Randhawa; T Wu; A Krasinskas; P Fontes; T Cacciarelli; A O Shakil; N Murase; J J Fung; T E Starzl
Journal:  Am J Surg Pathol       Date:  2004-05       Impact factor: 6.394

9.  Increasing transplant mass results in long-term allograft survival and recovery from transplant vasculopathy.

Authors:  De Shon Hall; Edda M Roberts; Sharon Ferguson; Zhuangzhi Wang; Joanna D Davies
Journal:  J Clin Immunol       Date:  2003-05       Impact factor: 8.317

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.